"Global divide in carbapenem resistance and hypervirulence of Klebsiella pneumonia: comparing trends in India and developed nations"- a comprehensive review.

The global health problem of carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CRKP) is exacerbated by the lack of effective treatments and increasing resistance. This study compares the clinical impact, resistance mechanisms, and prevalence of CR-hvKP in industrialized and emerging nations, analyzing 300 papers from national databases and selecting 70 for further examination. Treatment effectiveness, clinical outcomes, resistance mechanisms, and prevalence were assessed in the study, which concentrated on CRKP and hvKP strains that carried virulence genes (rmpA, aerobactin, yersiniabactin) and carbapenemase genes (blaKPC, blaNDM, blaOXA-12). With 25% of studies identifying blaOXA-48, 30% reporting blaKPC, and 45% tying blaNDM to resistance, analysis showed β-lactamase genes are mostly responsible for carbapenem resistance in Klebsiella pneumoniae strains. Resistance rates for CR-hvKP range from 4.4% to 100% in India, where the condition is disproportionately common. Clinical results are alarming: hospital-admitted patients had death rates ranging from 30% to 60% and morbidity rates as high as 90%. The study emphasizes how plasmid-mediated resistance, immune evasion mechanisms, and enhanced biofilm development contribute to the pathophysiology of CR-hvKP, making therapy more difficult. Urgent action is needed to battle CR-hvKP and lessen its catastrophic clinical impact, as it is more common in India than developed countries.